TherapeuticsMD (NASDAQ:TXMD) Now Covered by StockNews.com

Analysts at StockNews.com began coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a report released on Thursday. The firm set a “hold” rating on the stock.

TherapeuticsMD Stock Performance

Shares of NASDAQ:TXMD opened at $1.88 on Thursday. TherapeuticsMD has a 1 year low of $1.86 and a 1 year high of $4.73. The stock’s 50-day moving average is $2.22 and its 200 day moving average is $2.30.

Institutional Trading of TherapeuticsMD

A hedge fund recently bought a new stake in TherapeuticsMD stock. ADAR1 Capital Management LLC acquired a new stake in shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) during the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 272,160 shares of the company’s stock, valued at approximately $612,000. ADAR1 Capital Management LLC owned approximately 2.57% of TherapeuticsMD as of its most recent filing with the SEC. Hedge funds and other institutional investors own 30.74% of the company’s stock.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.